Answers are grounded in this paper and cite their sources.
Severe sepsis and multiorgan failure (MOF) are major causes of death in the ICU. The extracorporeal cytokine adsorption column (ECAC; Cytosorb®, CytoSorbents Corporation, USA), a critical care focused therapeutic device, results in rapid in vitro and in vivo elimination of several key cytokines and prevents organ failure. Use of ECAC in patients with sepsis is a new area of research with insufficient data to promote large prospective RCTs. Studies published to date have shown promising results. We report our clinical experience with ECAC for severe sepsis/septic shock/MOF patients.
No takes yet. Share an insight, caveat, or question.
Sakhavalkar et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: